AtaiBeckley (ATAI) drew fresh attention after reporting Phase 2a data for EMP-01 in Social Anxiety Disorder, showing symptom and avoidance reductions with no serious adverse events and positioning the program for further outpatient-focused development.

Against this backdrop, AtaiBeckley’s 1 month share price return of 10.71% and 90 day share price return of 4.68% suggest momentum has picked up recently. The 1 year total shareholder return of 179.86% points to strong longer term gains from a low base.

If this kind of clinical progress has your attention, it can be useful to see what else is moving in related areas using our 34 healthcare AI stocks

AtaiBeckley trades at US$4.03 with analyst targets implying a large gap, while the company is still loss making and early in its pipeline story. Is the stock mispriced, or is the market already banking on future growth?

Price to Book of 6.7x: Is it justified?

On a simple yardstick, AtaiBeckley’s P/B of 6.7x looks rich against the US pharmaceuticals sector average of 2.7x, even after the recent share price run.

The P/B ratio compares the company’s market value to its accounting book value. This is often a useful cross check for asset heavy or early stage companies that are not yet profitable. For AtaiBeckley, a high P/B comes alongside a very early revenue base of $4.1m and a reported net loss of $660.0m, so investors are clearly focusing more on the pipeline story and expected future cash flows than on current earnings.

Relative to peers, paying 6.7x book value versus 2.7x for the broader US pharmaceuticals industry suggests investors are pricing in a much stronger future outcome than the sector average. That premium sits against mixed signals, with the stock trading 33.9% below one DCF based fair value estimate and also priced 33.9% below another internal fair value measure, while forecasts still point to ongoing losses over the next three years. See what the numbers say about this price — find out in our valuation breakdown.

Result: Price to book ratio of 6.7x (OVERVALUED).

However, the story can change quickly if clinical trials stumble, or if ongoing losses and the US$1.48b valuation start to test investor patience.

Another View: Cash Flow Based Fair Value

The earlier P/B check painted AtaiBeckley as expensive versus the US pharmaceuticals sector, but the SWS DCF model points in the opposite direction. With the stock at $4.03 and our DCF fair value at $6.10, the shares trade 33.9% below that estimate. So is the market being cautious, or is this a mismatch in expectations?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AtaiBeckley for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Does this mix of optimism and concern match how you see AtaiBeckley, or does it feel off? Take a closer look at the numbers, act promptly if necessary, and weigh both sides with the help of 2 key rewards and 4 important warning signs

Looking for more investment ideas?

If AtaiBeckley has sharpened your interest, do not stop here. Broaden your watchlist with other focused stock ideas that could sharpen your overall portfolio thinking.

• Target higher quality at reasonable prices by scanning companies in the 49 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks in the 12 dividend fortresses.
• Aim for resilience first by checking companies highlighted in the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.